Forward with vaccines

WuXi Biologics signs on for long-term vaccine manufacturing contract
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SHANGHAI—May saw WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announce that it had entered into a strategic partnership letter of intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
 
WuXi Vaccines is a joint venture company to be established between WuXi Biologics and Shanghai-based Hile Bio-Technology. The business model of WuXi Vaccines is to build world-class integrated platforms and a contract development and manufacturing organization (CDMO) model to enable global companies to develop and manufacture vaccines.
 
Under the LOI, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing, drug product manufacturing and quality control labs.
 
“This is a historic moment for WuXi Biologics and WuXi Vaccines as well as for the global vaccine industry. Due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture, and process and quality control are extremely critical for the quality of the product. This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Biologics,” said Dr. Chris Chen, CEO of Wuxi Biologics. “Vaccine CDMO is one of the next growth areas for WuXi Biologics. Once this project is initiated, our vaccine business will contribute substantially to the growth of WuXi Biologics.”

Related Topics

Published In

Volume 15 - Issue 6 | June 2019

June 2019

June 2019 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue